Literature DB >> 16046070

A structural model of a seven-transmembrane helix receptor: the Duffy antigen/receptor for chemokine (DARC).

A G de Brevern1, H Wong, C Tournamille, Y Colin, C Le Van Kim, C Etchebest.   

Abstract

The Duffy antigen/receptor for chemokine (DARC) is an erythrocyte receptor for malaria parasites (Plasmodium vivax and Plasmodium knowlesi) and for chemokines. In contrast to other chemokine receptors, DARC is a promiscuous receptor that binds chemokines of both CC and CXC classes. The four extracellular domains (ECDs) of DARC are essential for its interaction with chemokines, whilst the first (ECD1) is sufficient for the interaction with malaria erythrocyte-binding protein. In this study, we elaborate and analyze structural models of the DARC. The construction of the 3D models is based on a comparative modeling process and on the use of many procedures to predict transmembrane segments and to detect far homologous proteins with known structures. Threading, ab initio, secondary structure and Protein Blocks approaches are used to build a very large number of models. The conformational exploration of the ECDs is performed with simulated annealing. The second and fourth ECDs are strongly constrained. On the contrary, the ECD1 is highly flexible, but seems composed of three consecutive regions: a small beta-sheet, a linker region and a structured loop. The chosen structural models encompass most of the biochemical features and reflect the known experimental data. They may be used to analyze functional interaction properties.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046070     DOI: 10.1016/j.bbagen.2005.05.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  24 in total

1.  3D structural models of transmembrane proteins.

Authors:  Alexandre G de Brevern
Journal:  Methods Mol Biol       Date:  2010

2.  "Pinning strategy": a novel approach for predicting the backbone structure in terms of protein blocks from sequence.

Authors:  A G De Brevern; C Etchebest; C Benros; S Hazout
Journal:  J Biosci       Date:  2007-01       Impact factor: 1.826

3.  A new prediction strategy for long local protein structures using an original description.

Authors:  Aurélie Bornot; Catherine Etchebest; Alexandre G de Brevern
Journal:  Proteins       Date:  2009-08-15

4.  Analysis of loop boundaries using different local structure assignment methods.

Authors:  Manoj Tyagi; Aurélie Bornot; Bernard Offmann; Alexandre G de Brevern
Journal:  Protein Sci       Date:  2009-09       Impact factor: 6.725

Review 5.  In silico studies on DARC.

Authors:  Alexandre G de Brevern; Ludovic Autin; Yves Colin; Olivier Bertrand; Catherine Etchebest
Journal:  Infect Disord Drug Targets       Date:  2009-06

6.  New opportunities to fight against infectious diseases and to identify pertinent drug targets with novel methodologies.

Authors:  Alexandre G de Brevern
Journal:  Infect Disord Drug Targets       Date:  2009-06

7.  Molecular evolution of a malaria resistance gene (DARC) in primates.

Authors:  Thiago Yukio Kikuchi Oliveira; Eugene E Harris; Diogo Meyer; Chong K Jue; Wilson Araújo Silva
Journal:  Immunogenetics       Date:  2012-03-07       Impact factor: 2.846

8.  Species-specific features of DARC, the primate receptor for Plasmodium vivax and Plasmodium knowlesi.

Authors:  Ann Demogines; Kimberly A Truong; Sara L Sawyer
Journal:  Mol Biol Evol       Date:  2011-08-30       Impact factor: 16.240

9.  Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth.

Authors:  Linda W Horton; Yingchun Yu; Snjezana Zaja-Milatovic; Robert M Strieter; Ann Richmond
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

10.  Modeling and molecular dynamics of HPA-1a and -1b polymorphisms: effects on the structure of the β3 subunit of the αIIbβ3 integrin.

Authors:  Vincent Jallu; Pierre Poulain; Patrick F J Fuchs; Cecile Kaplan; Alexandre G de Brevern
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.